1,593
Views
10
CrossRef citations to date
0
Altmetric
Respiratory

Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

, , , , , & show all
Pages 936-944 | Received 07 Mar 2016, Accepted 04 May 2016, Published online: 25 May 2016

Figures & data

Figure 1 Partitioned model structure.

Figure 1 Partitioned model structure.

Table 1. Source of efficacy inputs.

Table 2. Summary of model inputs.

Table 3. Base case results.

Table 4. Alternative scenarios.

Figure 2 Results of one-way sensitivity analysis.

Figure 2 Results of one-way sensitivity analysis.

Figure 3 Incremental cost-effectiveness plane of ceritinib vs alternatives.

Figure 3 Incremental cost-effectiveness plane of ceritinib vs alternatives.

Figure 4 Visual fit of reconstructed and/or observed KM curves and parametric functions.

Figure 4 Visual fit of reconstructed and/or observed KM curves and parametric functions.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.